Table 5.
Comparison among the newly developed triplex PPV, PRV and PCV-2 real time PCR assay with existing real time PCR assays using clinical samples.
| Clinical samples | Positive target(s) | Newly developed real time PCR |
BJCIQ real time PCR |
|||||
|---|---|---|---|---|---|---|---|---|
| Triplex of PPV, PRV and PCV-2 | PPV singular | PRV singular | PCV-2 singular | PPV | PRV | PCV-2 | ||
| 24 tonsil tissues positive for PPV | PPV | 24 | 24 | 0 | 0 | 24 | NT | NT |
| PRV | 3 | 0 | 3 | 0 | NT | NT | NT | |
| PCV-2 | 12 | 0 | 0 | 12 | NT | NT | NT | |
| PPV + PRV | 3 | 3 | 3 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 12 | 12 | 0 | 12 | NT | NT | NT | |
| PRV + PCV-2 | 3 | 0 | 3 | 3 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 3 | 3 | 3 | 3 | NT | NT | NT | |
| 24 tonsil tissues positive for PCV-2 | PPV | 10 | 10 | 0 | 0 | NT | NT | NT |
| PRV | 4 | 0 | 4 | 0 | NT | NT | NT | |
| PCV-2 | 24 | 0 | 0 | 24 | NT | NT | 24 | |
| PPV + PRV | 4 | 4 | 4 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 10 | 10 | 0 | 10 | NT | NT | NT | |
| PRV + PCV-2 | 4 | 0 | 4 | 4 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 4 | 4 | 4 | 4 | NT | NT | NT | |
| 16 lung tissues positive for PRV | PPV | 8 | 8 | 0 | 0 | NT | NT | NT |
| PRV | 14 | 0 | 14 | 0 | NT | 16 | NT | |
| PCV-2 | 5 | 0 | 0 | 5 | NT | NT | NT | |
| PPV + PRV | 7 | 7 | 7 | 0 | NT | NT | NT | |
| PPV + PCV-2 | 5 | 5 | 0 | 5 | NT | NT | NT | |
| PRV + PCV-2 | 5 | 0 | 5 | 5 | NT | NT | NT | |
| PPV + PRV + PCV-2 | 1 | 1 | 1 | 1 | NT | NT | NT | |
NT: Not tested. BJCIQ: Beijing Entry & Exit Inspection and Quarantine Bureau.